Get the Stockscreener App
146.23
1.26%
1.82
After Hours:
146.23
Biogen Inc Stock (BIIB) Latest News
Amyotrophic Lateral Sclerosis (ALS) Market Future Prospects, - openPR
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Petri Dish: A monthly Alzheimer's drug from Biogen; Watertown biotech CEO pay falls 66% - The Business Journals
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Smith Group Asset Management LLC Invests $306,000 in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed - Investing.com India
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates - Yahoo Finance
BMO Capital Adjusts Price Target on Biogen to $156 From $164, Keeps Market Perform Rating - Marketscreener.com
Leerink Partners Adjusts Biogen Price Target to $260 From $290, Maintains Outperform Rating - Marketscreener.com
Kirr Marbach & Co. LLC IN Cuts Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cancer Gene Therapy Market Outlook 2025-2032: Witness Booming - openPR
BIIB Stock Quote Price and Forecast - CNN
Chancery Bars More Disclosures In Sage-Biogen Fight - Law360
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up - Yahoo Finance
Multiple Sclerosis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion - Barchart
March 2026 Options Now Available For Biogen (BIIB) - Nasdaq
Sage rejects Biogen’s unsolicited bid, but open to other offers - The Pharma Letter
Breaking Down Biogen: 18 Analysts Share Their Views - Benzinga
Biogen (NASDAQ:BIIB) Given New $160.00 Price Target at Citigroup - MarketBeat
Sage rejects Biogen’s $469m takeover bid - Yahoo Finance
Court Place Advisors LLC Sells 2,913 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sage rejects Biogen takeover and launches review - pharmaphorum
Sage Rejects Biogen Bid but Could be Open to Other Offers - TipRanks
Is Biogen (BIIB) an Underappreciated Stock? - MSN
Sage Spurns Biogen, Turns Attention To Strategic Review - News & Insights
Sage rebuffs Biogen bid to take it over - BioPharma Dive
Sector Update: Health Care Stocks Gain Late Afternoon -January 27, 2025 at 04:04 pm EST - Marketscreener.com
Sector Update: Health Care Stocks Gain Monday Afternoon -January 27, 2025 at 02:11 pm EST - Marketscreener.com
Biogen, Eisai receive FDA nod for monthly Leqembi IV maintenance dosing - MM+M Online
FDA clears monthly dosing of Alzheimer’s drug Leqembi - BioPharma Dive
Generics companies successfully challenge Biogen’s Dutch Tecfidera patent - JUVE Patent
Stock Quote & Chart - Biogen | Investor Relations
Eisai and Biogen gain FDA approval for monthly Leqembi - The Pharma Letter
Biological Drugs Strategic Research Report 2024-2030, - GlobeNewswire
Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer - GlobeNewswire Inc.
Sage rejects Biogen’s buyout offer, but says it's open to deals - The Business Journals
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company - Reuters
Sage Therapeutics Turns Down Biogen's Unsuitable OfferNews and Statistics - IndexBox, Inc.
Global markets live: Nvidia, AT&T, Biogen, Tesla, Nokia... - Marketscreener.com
Sage rejects Biogen's $469 million takeover offer - MSN
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug - Reuters
Sage Rejects Biogen Bid, Launches Review of Alternatives - MarketWatch
Sage Therapeutics rejects Biogen bid, starts strategic review (SAGE:NASDAQ) - Seeking Alpha
Sage rejects Biogen's $469 million takeover offer By Reuters - Investing.com
Sage rejects Biogen's takeover offer, to explore strategic alternatives -January 27, 2025 at 09:28 am EST - Marketscreener.com
Sage Therapeutics Rejects Biogen Takeover Bid, Explores Strategic Alternatives - StockTitan
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Pacer Advisors Inc. - MarketBeat
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug - Zacks Investment Research
Biogen, Eisai Win Nod for Monthly Leqembi Maintenance Amid Stagnant Sales - BioSpace
Biogen (NASDAQ:BIIB) and Eisai Win FDA’s OK on Alzheimer’s Drug Dosing - TipRanks
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosing - Yahoo Finance
Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing - MarketWatch
US regulator OKs Eisai-Biogen Alzheimer's drug's continuous dosing - The Mainichi
This Week in Chancery Court: Biogen, T-Mobile, Repsol SA - Bloomberg Law
USFDA nod to Leqembi IV maintenance dosing for treatment of early Alzheimer's Disease: Eisai, Biogen - Medical Dialogues
Wedbush Comments on Biogen's FY2024 Earnings (NASDAQ:BIIB) - MarketBeat
Eisai and Biogen win approval for once-monthly Leqembi maintenance dosing - Endpoints News
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease - Biogen | Investor Relations
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease - PR Newswire
FDA and EMA review Biogen's higher dose SMA drug - MSN
Crossmark Global Holdings Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (XSGO:BIIB) Total Liabilities : $11,954 Mil (As of Sep. 2024) - GuruFocus.com
Grimes & Company Inc. Cuts Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush Weighs in on Biogen's Q4 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
FDA accepts sNDA for higher regimen nusinersen for spinal muscular atrophy - Contemporary Pediatrics
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):